Chairman of the Board of Directors of Virtual Arrays — Lev Leytes From ___ to 2000, Mr. Leytes was the Principal Founder, Chairman of the Board of Directors and Chief Executive Officer of LJL Biosystems, Inc. He was responsible for strategy, executive team building, venture capital financing, IPO on the NASDAQ Stock Exchange in 1998, and merger with Molecular Devices (NASDAQ: MDCC) in 2000, creating a combined enterprise with a market capitalization exceeding $1 billion upon merger. Mr. Leytes holds an M.S., Engineering, Moscow Engineering Institute. Vice President, Software R&D — Ilya Ravkin Dr. Ravkin brings 24 years experience developing biomedical image analysis systems. From 1988-1999, he worked in senior technical and engineering management positions at Applied Imaging, from start-up through IPO, where he developed and brought to market a range of proprietary products in the area of life science research. In 1993, he founded TOFRA, a supplier of optical automation products. Dr. Ravkin received his Ph.D. in Computer Science from the Electrical Engineering Institute, St. Petersburg. Vice President, Biology R&D — Simon Goldbard Dr. Goldbard has over 15 years. industrial experience directing development of products for infectious disease and genetics markets. From 1994 to 2000, he worked as Director of Product Development at Applied Imaging, and from 1991-1994 as Director of Research & Development at Medigene, developing products associated with reagents and cancer diagnosis systems. In 1986, he co-founded Genet Corp., a developer of DNA probe-based diagnostics, which Quantum Chemicals acquired in 1989. He holds a Ph.D. in Immunobiology from the Department of Biochemistry, Iowa State University. Vice President of Strategic Marketing — Katherine Tynan Dr. Tynan has 8 years of industrial experience directing product development of instrument and reagent systems and services for the life-sciences and diagnostics markets. From 1997-2001, she worked at Applied Biosystems in various roles, including Director of Business Development, and Group R&D Leader for GeneScan products. She was also involved in business consulting for Celera and Celera Diagnostics, both wholly owned subsidiaries of Applera Corp. From 1993-1996, she worked as the Director of Molecular Genetics for the diagnostic services company, Oncogenetics/Datagenetics (acquired by Impath in 1996), where she developed tests for diverse applications such as inherited genetic diseases, HLA typing, oncology and paternity testing. Dr. Tynan did post doctoral work at Stanford University and received her LLNL, and Ph.D. in Human Genetics from the University of Calgary. She also has attended Babson College's "Consortium for Executive Development".